Co-Authors
This is a "connection" page, showing publications co-authored by Nathan Peiffer-Smadja and France Mentré.
Connection Strength
0.505
-
Type 1 interferons as a potential treatment against COVID-19. Antiviral Res. 2020 06; 178:104791.
Score: 0.219
-
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
Score: 0.059
-
Corrigendum to "Review of trials currently testing treatment and prevention of COVID-19" [Clin Microbiol Infect 26.8 (2020) 988-998]. Clin Microbiol Infect. 2021 Mar; 27(3):499.
Score: 0.058
-
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial-authors' response. J Antimicrob Chemother. 2021 01 01; 76(1):277-279.
Score: 0.058
-
Rationale of a loading dose initiation for hydroxychloroquine treatment in COVID-19 infection in the DisCoVeRy trial. J Antimicrob Chemother. 2020 09 01; 75(9):2376-2380.
Score: 0.056
-
Review of trials currently testing treatment and prevention of COVID-19. Clin Microbiol Infect. 2020 Aug; 26(8):988-998.
Score: 0.055